Inhibitor combinations targeting KRAS effector signaling in KRAS-mutant pancreatic cancer

被引：1
|
作者：
Cox, Adrienne D. [1 ]
Goodwin, Craig M. [1 ]
Bryant, Kirsten L. [1 ]
Dagliyan, Irem [1 ]
George, Samuel D. [1 ]
Lucas, Kelly E. [1 ]
Gautam, Prson [2 ]
Wennerberg, Krister [2 ]
Der, Channing J. [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC 27515 USA
[2] Inst Mol Med Finland, Helsinki, Finland
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-SY20-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SY20-02
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Combination inhibitor strategies targeting KRAS effector signaling in KRAS-mutant pancreatic cancer.
    Ozkan-Dagliyan, Irem
    Goodwin, Craig M.
    Bryant, Kirsten L.
    George, Samuel D.
    Lucas, Kelly
    Gautam, Prson
    Wennerberg, Krister
    Cox, Adrienne D.
    Der, Channing J.
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 68 - 68
  • [2] Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
    Miyazaki, Satoru
    Kitazawa, Masato
    Nakamura, Satoshi
    Koyama, Makoto
    Yamamoto, Yuta
    Hondo, Nao
    Kataoka, Masahiro
    Tanaka, Hirokazu
    Takeoka, Michiko
    Komatsu, Daisuke
    Soejima, Yuji
    MOLECULAR ONCOLOGY, 2025, 19 (02) : 377 - 390
  • [3] A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
    Xiufeng Pang
    Mingyao Liu
    Chinese Journal of Cancer, 2016, 35 (11) : 571 - 573
  • [4] A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
    Pang, Xiufeng
    Liu, Mingyao
    CHINESE JOURNAL OF CANCER, 2016, 35 : 92
  • [5] Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer
    Feng, Juanjuan
    Lian, Zhengke
    Xia, Xinting
    Lu, Yue
    Hu, Kewen
    Zhang, Yunpeng
    Liu, Yanan
    Hu, Longmiao
    Yuan, Kun
    Sun, Zhenliang
    Pang, Xiufeng
    ACTA PHARMACEUTICA SINICA B, 2023, 13 (03) : 1145 - 1163
  • [6] Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer
    Juanjuan Feng
    Zhengke Lian
    Xinting Xia
    Yue Lu
    Kewen Hu
    Yunpeng Zhang
    Yanan Liu
    Longmiao Hu
    Kun Yuan
    Zhenliang Sun
    Xiufeng Pang
    Acta Pharmaceutica Sinica B, 2023, (03) : 1145 - 1163
  • [7] Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization
    Maruyama, Kohei
    Shimizu, Yuki
    Nomura, Yumi
    Oh-hara, Tomoko
    Takahashi, Yuki
    Nagayama, Satoshi
    Fujita, Naoya
    Katayama, Ryohei
    NPJ PRECISION ONCOLOGY, 2025, 9 (01)
  • [8] Utility of a selective SHP2-inhibitor in KRAS-mutant cancer
    Hao, H.
    Wang, H.
    Liu, C.
    Kovats, S.
    Velazquez, R.
    Lu, H.
    Pant, B.
    Lim, J.
    Fleming, M.
    Shirley, M.
    Lamarche, M.
    Moody, S.
    Silver-Brown, S.
    Caponigro, G.
    Abrams, T.
    Hammerman, P.
    Williams, J.
    Engelman, J.
    Goldoni, S.
    Mohseni, M.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E24 - E24
  • [9] Targeting the ERK-MYC signaling network for the treatment of KRAS-mutant cancers
    Der, Channing J.
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [10] Closing the door on KRAS-mutant lung cancer
    Cully, Megan
    NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (11) : 747 - 747
12345